Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


National Center for Complementary & Alternative Medicine

This article was originally published in The Tan Sheet

Executive Summary

Two statements of organization published in the Feb. 10 Federal Register, the second notice comprising a mission statement, and the first establishing the official structure of the center. Along with the Office of the Director, the center will have an Office of Administrative Operations; Office of Legislation, Policy and Analysis; Office of Communications and Public Liaison; and Division of Extramural Research, Training and Review. All 12 staffers at the former Office of Alternative Medicine will join the center; efforts to hire seven new employees have begun. Interviews for the director position have concluded, and a short list has been delivered to NIH Director Harold Varmus, MD, who will make the final decision; the position is expected to be filled by late March. OAM was elevated to center status last October ("The Tan Sheet" Oct. 26, 1998, p. 8). The House Appropriations/HHS subcommittee is scheduled to hold a hearing on the center's FY 2000 budget March 4

You may also be interested in...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts